WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1992011849) SWALLOWABLE PHARMACEUTICAL COMPOSITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1992/011849    International Application No.:    PCT/US1992/000195
Publication Date: 23.07.1992 International Filing Date: 13.01.1992
Chapter 2 Demand Filed:    22.07.1992    
IPC:
A61K 9/00 (2006.01), A61K 31/34 (2006.01), A61K 31/415 (2006.01), A61K 31/43 (2006.01), A61K 31/47 (2006.01), A61K 31/545 (2006.01), A61K 31/65 (2006.01), A61K 33/24 (2006.01)
Applicants: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US)
Inventors: CHAPURA, Francis, Bernard; (US).
MITRA, Sekhar; (US)
Agent: REED, T., David; The Procter & Gamble Company, Ivorydale Technical Ctr., 5299 Spring Grove Ave., Cincinnati, OH 45217-1087 (US)
Priority Data:
641,030 14.01.1991 US
Title (EN) SWALLOWABLE PHARMACEUTICAL COMPOSITIONS
(FR) COMPOSITIONS PHARMACEUTIQUES ABSORBABLES
Abstract: front page image
(EN)Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of a soluble bismuth-containing pharmaceutical agent (preferably a pharmaceutically-acceptable salt suitable for oral co-administration of bismuth and an H¿2? receptor blocking anti-secretory agent), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.
(FR)Compositions pharmaceutiques orales se présentant sous une forme posologique unitaire permettant une absorption (notamment des gélules) comprenant une dose sans danger et efficace d'un agent pharmaceutique contenant du bismuth soluble (de préférence un sel pharmaceutiquement acceptable permettant une co-administration orale de bismuth et d'un agent antisecrétoire bloquant les récepteurs de H¿2?), ainsi que facultativement une ou plusieurs matières porteuses pharmaceutiquement acceptables, la densité de tassement de l'unité posologique étant inférieure à environ 1 g/ml.
Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)